Biotech entity
Compass Pathways is most often covered alongside FDA, which appears in 3 of these 3 stories. The clearest coverage concentration is clinical-trial: 2 of 3 stories, with the rest divided among 1 other category. Each story carries 2.3 original sources on average, compared with 3.3 for the broader beat in this window.
Last mentioned: Mar 26, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 67 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Compass Pathways is most often covered alongside FDA, which appears in 3 of these 3 stories. The clearest coverage concentration is clinical-trial: 2 of 3 stories, with the rest divided among 1 other category. Each story carries 2.3 original sources on average, compared with 3.3 for the broader beat in this window. Across a 17-day span, the pace is roughly 1.2 stories per week. At 6.3, the average consequence score sits above the same-window beat average of 6.1. This profile follows 3 Biotech stories mentioning Compass Pathways across the period from March 10, 2026 to March 26, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 251 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Compass Pathways. Shared-story counts are live from our verified record — not editorial picks.
King County Resolution
King County Council officially passes the resolution to decriminalize psychedelic mushrooms county-wide.
WA SB 5263 Passed
Washington Governor signs a bill to create a psilocybin task force and pilot program.
Seattle Decriminalization
Seattle City Council passes a resolution to decriminalize the cultivation and possession of psychedelic plants.
King County has officially passed a resolution to decriminalize the possession and use of psychedelic mushrooms, joining a growing list of Pacific Northwest jurisdictions. This move reflects a significant shift toward viewing psilocybin through a public health lens, potentially paving the way for expanded clinical research and therapeutic access in the region.
A new comparative study reveals that psychedelic-assisted therapy significantly exceeds the efficacy of standard nicotine patches for long-term smoking cessation. The findings suggest a paradigm shift in treating nicotine addiction, moving from continuous replacement to episodic, transformative intervention.
A landmark study has demonstrated that a single dose of psilocybin, paired with psychological support, significantly outperforms traditional nicotine replacement therapies for long-term smoking cessation. The findings suggest a paradigm shift in treating substance use disorders through psychedelic-assisted therapy.
Compass Pathways is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
